TWO-DRUG

REGIMEN

It might be all you need to treat HIV.1

Learn more about 2DR today.

WHAT IS A 2-DRUG REGIMEN TO TREAT HIV?

Treating HIV has come a long way in the past 20+ years, and with the right treatment and care, a person newly diagnosed with HIV in their 20s could potentially be on treatment for 60 years.2,3
Different classes of medications, called antiretroviral therapy, are needed to treat HIV and achieve an undetectable HIV status in the body.4
Today, a once-daily 2-drug regimen might be all you need to treat HIV.5,6
wow
question

WHY 2-DRUG REGIMEN COULD BE YOUR TREATMENT FOR HIV? 5-8

schedule
Convenient once-daily dosing, at any time of day with or without food.
medicine
May help with the side-effects associated with your current HIV regimen.
done
Reduced potential for interactions with other medications.

HOW DOES A 2-DRUG REGIMEN TREAT HIV?

The combination of Tivicay + lamivudine blocks the viral life cycle at two different targets and helps control HIV viral load.4,5

Since your body processes these two medicines at a similar rate, there's also a lower chance of drug resistance developing. Tivicay + lamivudine combination has been studied and recommended for people who are newly diagnosed with HIV,* and those who've switched from other treatments.2,9-11

doctor
Like all medicines, Tivicay + Lamivudine may cause side effects, although not everybody gets them. Common side effects people may experience are headache, nausea, and diarrhoea. 5,6

Ask your doctor if a 2-drug regimen is right for you.

To help you start this conversation, we’ve prepared these handy resources…
DOWNLOAD BELOW
FOR INFORMATION ABOUT TIVICAY CLICK ON THE LOGO
*Exclusions for treatment-naïve patients: HIV viral load >500,000 copies/mL, HBV co-infection, where ART is to be started before the results of HIV genotype resistance testing for reverse transcriptase or HBV testing are available.
Abbreviations:
HIV, human immunodeficiency virus; 2DR, two-drug regimen; HBV, hepatitis B virus; ART, antiretroviral therapy.
References:
1. Cahn P, et al. AIDS 2022;36(1):39-48. 2. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV, January 2022. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf (accessed November 2022). 3. Antiretroviral Therapy Cohort Collaboration (ARTCC). Lancet HIV 2017;4(8):e349-e356. 4. Chawla A, et al. Infect Dis Ther 2018 Jun;7(2):183-195. 5. GlaxoSmithKline NZ, Tivicay Consumer Medicine Information. 2019. Available at: https://www.medsafe.govt.nz/consumers/CMI/t/tivicay.pdf (accessed 21 March 2023). 6. GlaxoSmithKline NZ, 3TC Consumer Medicine Information. 2023. Available at: https://www.medsafe.govt.nz/Consumers/cmi/3tc.pdf (accessed 21 March 2023). 7. University of Liverpool. HIV Drug Interactions. Available at: https://www.hiv-druginteractions.org/checker (accessed 03 March 2023). 8. van Wyk J. Clin Infect Dis 2020;1-10. 9. Min S, et al. Antimicrob Agents Chemother 2010;54(1):254-258. 10. Moore KH, et al. AIDS 1999;13(16):2239-2250. 11. European AIDS Clinical Society (EACS Guidelines). Initial combination regimen for ART-naïve adults, October 2022 (version 11.1). Available at: https://www.eacsociety.org/media/guidelines-11.1_final_09-10.pdf (accessed 03 March 2023).
TIVICAY (dolutegravir sodium), 50 mg film-coated tablets, is an integrase inhibitor, used for the treatment of Human Immunodeficiency Virus (HIV) infection in combination with other anti-HIV agents in adults and children over 12 years of age and weighing 40 kg or more. Tivicay is a funded medicine; Special Authority criteria apply. DOVATO (dolutegravir and lamivudine) is a film coated tablet containing 50 mg of dolutegravir (as dolutegravir sodium) and 300 mg of lamivudine, which is used for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and adolescents (from 12 years of age weighing at least 40 kg) who have no known or suspected resistance to either antiretroviral component. Dolutegravir is an integrase inhibitor active against Human Immunodeficiency Virus (HIV). Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) and is a potent, selective inhibitor of HIV-1 and HIV-2. Dovato is not funded and is not supplied in New Zealand, this treatment option is available as separate medicines: Tivicay + Lamivudine. TIVICAY and DOVATO are both prescription medicines. Tivicay and Dovato have risks and benefits and should only be prescribed by a doctor experienced in treating HIV. Ask your doctor if TIVICAY or DOVATO is right for you. Use strictly as directed. If you have concerns, symptoms continue or if you have side effects, see your doctor, pharmacist or healthcare professional. Normal doctor's consultation fees apply. You can view full Consumer Medicine Information at www.medsafe.govt.nz. Trademarks are owned by or licensed to the ViiV Healthcare group of companies. ©2023 ViiV Healthcare group of companies or its licensor. Marketed on behalf of ViiV Healthcare by GlaxoSmithKline NZ Limited, Auckland. Adverse events involving ViiV Healthcare products should be reported to ViiV Healthcare Medical Information on 0800 808 500. Date of Approval: May 2023 and Date of Expiry: May 2025. TAPS-NP19322 PM-NZ-DLM-WCNT-230002.

This site is intended for New Zealand audience only.